(SRDX) Surmodics Inks Licensing Deal With Roche

October 9th, 2009

On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use in drug/device combination products in chosen markets.

Under the terms of the agreement, SurModics is entitled to an up-front payment of $3.5 million. Furthermore, the deal could be worth up to $200 million in delayed payments if multiple products are successfully developed. SurModics will also receive royalties on product sales. SurModics will receive payments for its development services. Under the terms of the agreement, Roche and Genentech have the right to obtain manufacturing services from SurModics.

The transaction provides Roche and Genentech complete access to the biodegradable microparticles developed by SurModics. They intend to use the products in a long-lasting version of their optical drug Lucentis (ranibizumab injection), a prescription medicine approved for treating patients with wet age-related macular degeneration.

Lucentis, discovered by Genentech, is being co-developed with Novartis Ophthalmics Business Unit for eye related diseases or disorders. Genentech has commercial rights in the United States and Novartis (NVS) for the rest of the world.

We believe the deal provides further opportunities to Roche, one of the world’s biggest drugmakers, and Genentech, which was acquired in 2008, to develop additional compounds for the treatment of ophthalmic diseases. This will broaden the treatment opportunities for patients suffering from eye diseases.

The news had a positive effect on SurModics and its shares rose by over 19%, closing Tuesday at $29.04.

SurModics, which provides surface modification and drug delivery technologies to medical device and pharmaceutical companies, competes mainly with Angiotech Pharmaceuticals Inc. (ANPI).

Zacks Investment Research
View original at: Zacks.com News Feed

More on this topic (What's this?)
BioCryst takes on Tamiflu (tickerspy.com, 9/14/09)
The Impact of the Genome (Contrarian Profits, 8/18/09)
Still Plenty of Upside for Biota (Fusion Investing and Analysis, 7/16/09)
Roche Keeps M&A Party Rolling with $46.8 Billion Deal for Genentech (Money Morning, 3/13/09)
Read more on SurModics, Roche Pharmaceuticals at Wikinvest

Related Posts:

  1. (AZN) AstraZeneca and Nektar Therapeutics Deal to Add ValueRecently, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of...
  2. (NCR) NCR Corporation Inks Deal With U.S. AirwaysNCR Corporation (NCR) signed a deal with US Airways, whereby the later will deploy NCR...
  3. (AZN) AstraZeneca Signs Licensing Deal With Nektar TherapeuticsYesterday, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of...
  4. (HAE) Haemonetics Corporation Inks Software DealHaemonetics Corp. (HAE) yesterday announced that it has entered into a deal with Blood Centers...
  5. (EPD) Enterprise Products Partners Inks New ContractYesterday, Enterprise Products Partners L.P. (EPD) signed a long-term agreement with one of the largest...
  6. (EAT) uWink Signs Software Licensing Deal with Chili’s, Also Opens 3rd RestaurantOn Monday September 22, uWink (NASDAQ: UWKI.OB) announced their second software licensing deal to install...


Search Posts by Tag: | | | | | | Diagnostic Substances | Healthcare

RSS Feeds by Tag: Angiotech Pharmaceuticals Inc | ANPI | Novartis AG | NVS | SRDX | SurModics Inc. | Diagnostic Substances | Healthcare |

Other Posts by: | RSS Feed for this author